BIOMAT Database Logo BIOMAT Database Logo

Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. 2010

Richard Eastell, and Peiqi Chen, and Kenneth G Saag, and Alan L Burshell, and Mayme Wong, and Margaret R Warner, and John H Krege
University of Sheffield Bone Metabolism Group, Metabolic Bone Centre, Sorby Wing, Northern General Hospital, Herries Road, Sheffield, S5 7AU, UK. r.eastell@sheffield.ac.uk

Reduced osteoblast function is a primary defect in glucocorticoid-induced osteoporosis (GIO), and is reflected by decreased biochemical markers of bone formation, such as serum osteocalcin (OC) and procollagen type I N-terminal propeptide (PINP). This analysis compared the effects of teriparatide and alendronate on OC and PINP in patients with GIO. In a double-blind study, women (N=159) and men (N=38) with GIO were randomized to either teriparatide 20 mug/day by subcutaneous injection or to alendronate 10 mg/day orally. OC and PINP were measured in fasting-state serum samples obtained at baseline and at 1, 6, 18, and 36 months. Baseline bone formation markers were below the reference interval (low) in 33% of patients for OC and in 4% of patients for PINP. On teriparatide therapy, the median OC and PINP levels increased by 92% and 108%, respectively, and this resulted in only 12% and 1% of patients being low at 6 months. On alendronate therapy, the median OC and PINP levels decreased by 40% and 53%, respectively, and this resulted in 68% and 34% of patients being low at 6 months. We conclude that bone formation as determined by surrogate markers was increased in teriparatide-treated patients with GIO and decreased in alendronate-treated patients with GIO.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010012 Osteogenesis The process of bone formation. Histogenesis of bone including ossification. Bone Formation,Ossification, Physiologic,Endochondral Ossification,Ossification,Ossification, Physiological,Osteoclastogenesis,Physiologic Ossification,Endochondral Ossifications,Ossification, Endochondral,Ossifications,Ossifications, Endochondral,Osteoclastogeneses,Physiological Ossification
D010024 Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis. Age-Related Osteoporosis,Bone Loss, Age-Related,Osteoporosis, Age-Related,Osteoporosis, Post-Traumatic,Osteoporosis, Senile,Senile Osteoporosis,Osteoporosis, Involutional,Age Related Osteoporosis,Age-Related Bone Loss,Age-Related Bone Losses,Age-Related Osteoporoses,Bone Loss, Age Related,Bone Losses, Age-Related,Osteoporoses,Osteoporoses, Age-Related,Osteoporoses, Senile,Osteoporosis, Age Related,Osteoporosis, Post Traumatic,Post-Traumatic Osteoporoses,Post-Traumatic Osteoporosis,Senile Osteoporoses
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011347 Procollagen A biosynthetic precursor of collagen containing additional amino acid sequences at the amino-terminal and carboxyl-terminal ends of the polypeptide chains. Protocollagen,Procollagen Type M
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D005938 Glucocorticoids A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. Glucocorticoid,Glucocorticoid Effect,Glucorticoid Effects,Effect, Glucocorticoid,Effects, Glucorticoid
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Richard Eastell, and Peiqi Chen, and Kenneth G Saag, and Alan L Burshell, and Mayme Wong, and Margaret R Warner, and John H Krege
Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide.
September 2016, Arthritis & rheumatology (Hoboken, N.J.),
Richard Eastell, and Peiqi Chen, and Kenneth G Saag, and Alan L Burshell, and Mayme Wong, and Margaret R Warner, and John H Krege
Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
March 2008, The New England journal of medicine,
Richard Eastell, and Peiqi Chen, and Kenneth G Saag, and Alan L Burshell, and Mayme Wong, and Margaret R Warner, and John H Krege
Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
March 2008, The New England journal of medicine,
Richard Eastell, and Peiqi Chen, and Kenneth G Saag, and Alan L Burshell, and Mayme Wong, and Margaret R Warner, and John H Krege
Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
November 2007, The New England journal of medicine,
Richard Eastell, and Peiqi Chen, and Kenneth G Saag, and Alan L Burshell, and Mayme Wong, and Margaret R Warner, and John H Krege
Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
March 2008, The New England journal of medicine,
Richard Eastell, and Peiqi Chen, and Kenneth G Saag, and Alan L Burshell, and Mayme Wong, and Margaret R Warner, and John H Krege
Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
April 2010, Bone,
Richard Eastell, and Peiqi Chen, and Kenneth G Saag, and Alan L Burshell, and Mayme Wong, and Margaret R Warner, and John H Krege
Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.
January 2010, The Journal of rheumatology,
Richard Eastell, and Peiqi Chen, and Kenneth G Saag, and Alan L Burshell, and Mayme Wong, and Margaret R Warner, and John H Krege
Is teriparatide or alendronate the best treatment for glucocorticoid-induced osteoporosis?
May 2008, Nature clinical practice. Rheumatology,
Richard Eastell, and Peiqi Chen, and Kenneth G Saag, and Alan L Burshell, and Mayme Wong, and Margaret R Warner, and John H Krege
New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide.
January 2014, Bone research,
Richard Eastell, and Peiqi Chen, and Kenneth G Saag, and Alan L Burshell, and Mayme Wong, and Margaret R Warner, and John H Krege
Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
November 2006, The New England journal of medicine,
Copied contents to your clipboard!